Drug Companies Update Mar 2008
Mergers, acquisitions & Joint Ventures
- Biopharmaceutical company Celgene has acquired Pharmion corporation.
- Nycomed Pharma has acquired specialty pharmaceutical company Bradley Pharmaceuticals.
- SurroMed has changed its name to Alavita Pharmaceuticals.
- Privately held biopharmaceutical company Immusol, has changed its name to ItherX Pharmaceuticals.
- Pharmaceutical giant Pfizer has acquired CovX.
New Companies
- Advanced Cancer Therapeutics is a pharmaceutical company focused on the discovery and early development of cancer therapeutics.
- Privately-owned Alphamed Pharmaceuticals is engaged in the development of prescription and over-the-counter products for human and animal use.
- Asphelia is a private company developing clinical-stage immunotherapeutics for immunological and inflammatory disorders.
- BIND Biosciences is engaged in the development of targeted nanoparticle drugs, for the treatment of cancer, cardiovascular disease and inflammatory disease.
- Blasticon is a biotechnology company, focusing on the development of diagnostics and cellular therapies based on its patented technology to reduce monocytes from venous blood into blastocytes.
- Cervelo specializes in the development and in-licensing of neurological therapeutics.
- Mattern Pharmaceuticals is focused on developing sustained-release intra-nasal products for the treatment of psyconeuroendocrinology disorders.
- Osta Biotechnologies is engaged in the development of novel therapeutic and diagnostic products for Alzheimer's disease, cancer, osteoporosis and X-linked hypophosphataemic rickets.
- Pluristem Therapeutics is involved in the commercialization of allogenic stem cell therapies for the treatment of several severe degenerative, malignant and autoimmune diseases.
- Sirnaomics is a biopharmaceutical company focused on multi-targeted siRNA for the treatment of a range of diseases.
- TxCell is engaged in the development of therapies for inflammatory and autoimmune diseases.
- 3SBio is a biopharmaceutical company focused on the development of compounds for use in oncology and nephrology.
- Argyll Biotechnologies aims to create highly-effective and affordable treatments for autoimmune and neurological disorders.
- German outfit Cytavis BioPharma was formed in 2005 to develop non-MAb protein therapeutics for use in cancer.
- Privately-owned Emmaus Medical is engaged in the development and commercialization of treatment and therapies for rare conditions such as sickle-cell disease.
- Genocea Biosciences is focused on the discovery and devleopment of vaccines for a variety of infectious diseases.
- IMED AB develops human Mabs that induce or block apoptosis for a range of diseases including cancer, transplantation regection and HIV.
- Lixte Biotechnology is a pharmaceutical company focused on the development of cancer therapeutics and diagnostics.
